Mauna Kea Technologies Welcomes Benoit Chardon as Senior Advisor to Scale its Irritable Bowel Syndrome and Food Intolerance Business - Seite 2

"We couldn’t be more excited to welcome Benoit in our team, as we work towards the scaling of our IBS and food intolerance application. Our aspirations in this indication are bold and potentially game-changing for our company, and it is crucial to have a team of exceptional caliber to navigate us towards success”, said Sacha Loiseau, Ph.D., Founder, Chairman and Chief Executive Officer of Mauna Kea Technologies. “Benoit's unparalleled expertise makes him the ideal person for Mauna Kea as we embark on a patient-centric approach. His innovative leadership and strategic execution at Allurion have led to the Company's remarkable development, which fits with our ambition at Mauna Kea. With a clear strategy in place, we eagerly anticipate sharing progress updates with our stakeholders in the near term."

About IBS

Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder, affecting 9 to 15% of the population and characterized by a group of symptoms including abdominal pain, bloating, and changes in bowel habits (diarrhea, constipation, or both), without any underlying damage visible through standard diagnostics. IBS significantly affects the quality of life of sufferers who often face a protracted and distressing journey of medical consultation that could last 2 to 3 years on average with no guaranteed path to identifying the underlying cause of their symptoms. Its management often requires a multidisciplinary approach, including dietary changes, medication, and psychological support, reflecting the complex interplay between the gut and the brain.

In several important clinical studies¹ using Confocal Laser Endomicroscopy, it has been proved that 50% to 60% of IBS patients could in fact suffer from atypical food intolerances that can only be characterized by the real time visualization with Cellvizio of the intestinal barrier during a food challenge.

For more information on the use of Cellvizio in food intolerance, please visit our website: www.maunakeatech.com/en/physicians/62-irritable-bowel-syndrome

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.